Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 780.19

-0.6%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biotech Jim who wrote (1674)	11/10/2014 11:50:32 AM
From: Miljenko Zuanic	Read Replies (1) of 3559

This morning we have good news, AMGN-NDA accepted for review by FDA, for the short term “surrogate” indication, without(?) or with “minimal" medical claim. Now, I believe that FDA staff has in advance results from IMPROVE-IT, and that results are: “good trend toward medical benefit”! This leave REGN with chance to file NDA with “partial medical claim”, because by 2015-mid-year they will have advance “post-hock” outcome results from 18(24) months-safety study. finance.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next